Gefitinib plus docetaxel in non-small-cell lung cancer

The Lancet

Volumn 373, Issue 9663, 2009, Pages 541-

  Zalcman, Gérard ^a   Bergot, Emmanuel ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PACLITAXEL; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TAXOID; TUMOR MARKER;

CLINICAL TRIAL; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LUNG NON SMALL CELL CANCER; MUTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PUBLICATION; TUMOR GROWTH; DRUG EFFECT; GENETICS; LUNG TUMOR; MORTALITY; NOTE; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 59749083867     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60192-6     Document Type: Letter

References (2)

1. Kim E.S., Hirsh V., Mok T., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372 (2008) 1809-1818
2. Douillard J.-Y., Hirsh V., Mok T., Socinski M.A., et al. Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small-cell lung cancer (INTEREST). J Clin Oncol (Meeting Abstracts) 26 (2008) 8001